Why the study?
Does the PFA-100 device accurately screen for platelet function disorders and von Willebrand disease in referred patients?
Does the PFA-100 device accurately screen for platelet function disorders and von Willebrand disease in referred patients?
The PFA-100 device provides acceptable sensitivity and negative predictive value for screening platelet function disorders and von Willebrand disease, though its specificity and positive predictive value are diminished in patients with low hemoglobin.
Answers are grounded in this paper and cite their sources.
May support ruling out disorders in referred patients; leaves open prospective validation before routine use.
Two hundred and five patients referred for evaluation of platelet functions and 126 healthy controls were tested with the PFA-100 instrument. A cut-off value of 150 s for collagen/epinephrine (CEPI) closure time (CT) produced most acceptable sensitivity (90%), specificity (85.2%), and positive (82.6%) and negative (91.6%) predictivity values for screening of platelet function disorders and von Willebrand disease (vWD). All patients with vWD and Glanzmann thrombasthenia could be detected by PFA-100. Both CEPI and collagen/adenosine diphosphate (CADP) CTs were elevated in all of these cases. Sensitivity of the device was 81.6% for patients with platelet secretion defects. CADP CT was normal in 63.9% of the patients in this subgroup. Specificity (47%) and positive predictivity (57%) of the instrument were diminished in patients with low hemoglobin concentrations. Depending on the results, an algorithm was developed for screening of platelet function disorders and vWD with PFA-100.
No takes yet. Share an insight, caveat, or question.
Büyükaşık et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: